Cytek Biosciences, Inc. CTKB
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -533.36% | -1,158.64% | -557.63% | -1,005.30% | -26.18% |
| Total Depreciation and Amortization | 2.38% | 4.19% | 9.07% | 14.16% | 14.73% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 872.72% | 454.99% | 320.90% | 314.31% | -74.27% |
| Change in Net Operating Assets | 156.09% | 204,966.67% | -86.79% | -162.15% | -172.74% |
| Cash from Operations | -243.64% | -139.72% | -134.26% | -118.46% | -105.83% |
| Capital Expenditure | -73.30% | -39.51% | -41.92% | -15.86% | 3.73% |
| Sale of Property, Plant, and Equipment | 10.89% | -23.51% | -29.91% | -12.50% | 155.67% |
| Cash Acquisitions | -- | -- | -- | -- | -99.58% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 63.86% | 103.50% | 66.72% | 117.60% | -442.69% |
| Cash from Investing | 53.96% | 96.54% | 61.02% | 112.19% | -640.41% |
| Total Debt Issued | 9.12% | 77.10% | 186.45% | 33.51% | 397.92% |
| Total Debt Repaid | -300.57% | -187.11% | -111.57% | -751.89% | -248.39% |
| Issuance of Common Stock | 40.72% | -8.78% | -35.35% | -45.79% | -42.90% |
| Repurchase of Common Stock | 95.93% | 97.69% | 84.05% | 28.97% | 54.64% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 108.71% | 113.00% | 107.23% | 15.11% | 65.50% |
| Foreign Exchange rate Adjustments | 1,212.56% | 323.00% | 23.24% | -97.59% | -90.19% |
| Miscellaneous Cash Flow Adjustments | -- | 300.00% | -- | -- | -- |
| Net Change in Cash | 62.20% | 98.42% | 59.87% | 88.54% | -5,105.28% |